Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11283)	8/17/1999 1:54:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

George w, the "preliminary" data should come out. Nothing else could save what little hope for this drug one has now. Xoma is wrongly not releasing the data. I e-mailed Xoma asking for release of the data. I will call by phone early. Cephalon 's Myothrophin problem were after filling, any data before? Interneuron's Ceraxon problem was before submission, data came out non officially later. AMLN, LGND, Pfe, lipo, even ABTI put lots of the data out. Surprisingly, Zonagen was putting part of their data out early ,and later without any problem. Zonagen actually publish the best data and raise $60 millions on a secondary offering. Part of the poor data was presented later in a conference. Stock tumbles back and forth. Surprinsingly, Zonagen was more clear than Xoma. Xoma should not wait to market open to clarify Ellen quotations in Bloomberg.